ArticleAnnals of medicine2026
Suicide mortality in metabolic dysfunction-associated liver diseases: a nationwide cohort study.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated alcohol-related liver disease (MetALD) are becoming more recognised as common chronic liver conditions. Despite this, their relationship with suicide mortality has not been thoroughly investigated.
methodsWe conducted a nationwide population-based cohort study involving 4,348,487 Korean adults who underwent health screening in 2012. Participants were categorised into four groups based on fatty liver index, metabolic risk factors, and alcohol consumption: no steatotic liver disease (no SLD,
resultsDuring a median follow-up of 9.2 years, 9,830 participants died by suicide. Compared to individuals without SLD, the adjusted HRs for suicide mortality were significantly elevated across all SLD subtypes: 1.20 (95% CI: 1.12-1.29) for MASLD, 1.39 (95% CI: 1.23-1.57) for MetALD, and 1.39 (95% CI: 1.11-1.74) for ALD. A dose-dependent increase in suicide mortality was observed with higher levels of alcohol consumption. Even among individuals with low alcohol intake, SLD remained associated with a higher risk of suicide compared to non-SLD (HR: 1.24; 95% CI: 1.15-1.33).
conclusionsBoth MASLD and MetALD were associated with a higher risk of suicide mortality. These findings highlight the combined effects of metabolic dysfunction and alcohol use on suicide risk within these populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.